Keep Me Logged In
Joe Jimenez, CEO of Novartis, confirms the company's 2014 outlook, saying sales growth will be in the mid-single digits in the "worst case scenario" that there is generic competition to its blood pressure pill Diovan "relatively soon".
Got a confidential news tip? We want to hear from you.
Sign up for free newsletters and get more CNBC delivered to your inbox
© 2019 CNBC LLC. All Rights Reserved. A Division of NBCUniversal
Data is a real-time snapshot *Data is delayed at least 15 minutes. Global Business and Financial News, Stock Quotes, and Market Data and Analysis.
Data also provided by